Early modulation of pituitary gonadotropins during PD-1 inhibitor–based immunochemotherapy in patients with solid tumors
This longitudinal study reveals that PD-1 inhibitor-based immunochemotherapy in patients with lung and colorectal cancer induces selective, progressive alterations in pituitary hormones (specifically increasing FSH and prolactin while decreasing the LH/FSH ratio) without causing significant changes in circulating gonadal sex steroids, suggesting a primary pituitary-level endocrine response rather than overt gonadal dysfunction.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine your body's hormone system as a high-tech orchestra. At the top of the concert hall sits the Pituitary Gland, the conductor. Down in the orchestra pit are the Gonads (the ovaries and testes), the musicians playing the sex hormone instruments. Normally, the conductor shouts instructions to the musicians, and they play their notes (like testosterone or estrogen) in perfect harmony.
Now, imagine a new kind of treatment for lung and colorectal cancer called PD-1 inhibitor immunochemotherapy. It's like sending a super-charged immune team into the body to fight the tumor. But what happens to the orchestra when this new team arrives?
A team of researchers from Guangzhou University of Chinese Medicine decided to listen closely to the music over time. They tracked 34 patients (24 men and 10 women) with lung or colorectal cancer who were getting this specific treatment. They checked the "volume" of the conductor's signals and the musicians' notes at the start, and then again after 3, 6, and 9 weeks.
Here is what they found, played out like a story:
The Conductor Gets Loud, But the Musicians Stay Quiet
The most surprising thing happened to the conductor (the pituitary gland). Specifically, the part of the conductor that controls the "FSH" signal started turning up the volume significantly.
- At the start, the median FSH level was 12.97.
- By week 6, it had climbed to 22.21.
- By week 9, it reached 24.36.
The researchers say this increase is statistically significant, meaning it's a real change, not just a random fluke. The LH signal (another part of the conductor) also tried to get louder, but it was much shyer. It only reached a level that was definitely different from the start by week 9 (14.44 compared to the starting 10.13).
Because the FSH signal got much louder than the LH signal, the ratio between them dropped. It's as if the conductor started shouting "FSH!" much more often than "LH!"
But here is the twist: Even though the conductor was shouting louder and changing the rhythm, the musicians in the pit didn't change their tune at all.
The levels of the actual sex hormones—testosterone, estradiol, and progesterone—stayed remarkably stable.
- Testosterone stayed around 8.81 at the start and 13.49 (in the lung cancer group) by week 9, with no big statistical shift.
- Estradiol and progesterone also showed no significant longitudinal changes.
This suggests that the treatment is messing with the instructions coming from the brain (the pituitary), but it isn't breaking the musicians (the gonads) themselves. The body is adjusting the volume of the signals, but the actual hormone production remains steady.
The "Prolactin" Surprise
There was another instrument in the orchestra that got very loud: Prolactin.
- In the overall group, Prolactin levels rose significantly over time.
- In the Lung Cancer group, Prolactin started at 277.10. By week 6, it jumped to 441.60, and by week 9, it soared to 557.10. This was a delayed and progressive rise; it didn't spike immediately after the first dose but built up significantly by the later weeks.
- In the Colorectal Cancer group, the pattern was different. Prolactin levels actually showed a significant increase as early as week 3 (rising from a baseline of 448.40 to 484.00), before stabilizing later in the treatment.
So, while the timing of the Prolactin rise varied between the two cancer types, the overall trend showed that this hormone did increase significantly during treatment, reflecting a complex interaction between the immune system and the brain's chemistry.
Not Everyone Plays the Same Song
The researchers noticed that the "music" sounded different depending on who was playing.
- Men (24 patients): They showed the clearest changes. Their FSH and LH signals climbed steadily, and their Prolactin levels rose significantly by weeks 6 and 9.
- Women (10 patients): These were all postmenopausal women. Their hormone levels were already high at the start (like a conductor who is already shouting). Because of this, the treatment didn't seem to change their levels as dramatically. Their hormones mostly just "fluctuated minimally," staying relatively stable.
Different Cancers, Different Reactions
The type of cancer mattered, too.
- Lung Cancer Patients: They showed the big changes in FSH and a progressive, delayed rise in Prolactin.
- Colorectal Cancer Patients (11 patients): They were much calmer regarding LH, but their FSH did rise significantly (from 19.90 to 35.50 by week 9). Notably, their Prolactin response was faster, showing a significant jump early on (week 3) rather than the delayed surge seen in lung cancer patients.
What This Means (and What It Doesn't)
The authors are careful not to call this a "cure" or a "disaster." They suggest that this treatment causes selective early changes in the pituitary gland. They argue against the idea that the treatment causes immediate, obvious gonadal failure (where the musicians stop playing entirely).
Instead, they propose that the immune therapy might be creating a kind of "neuroendocrine stress" that makes the pituitary gland work a little harder or differently, but the body's hormone factories are still running smoothly.
The researchers admit that because the study was retrospective (looking back at past records) and had a small sample size, these findings are more like a hypothesis or a clue for future studies rather than a final, proven rule. They didn't simulate this; they measured real patients, but they need more data to be sure.
So, in the end, the paper tells us that while the "conductor" of the hormone orchestra gets a bit rowdy during this cancer treatment, the "musicians" keep playing their song just fine. It's a subtle shift in the brain's signals, not a breakdown of the body's hormone production.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.